Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCNU Wafer, Irinotecan, and Bevacizumab for Recurrent GBM
NCT00984438Phase 2Withdrawn
- Sponsor
- University of Cincinnati
- Start
- Jun 2009
- Primary completion
- Jun 2010
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carmustine, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, bevacizumab in glioblastoma multiforme (GBM), sponsored by University of Cincinnati. Planned start Jun 2009; status: withdrawn.
02
Drugs
carmustineirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabbevacizumab
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00984438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00984438.